Genmab A+s

H. Lundbeck A/s

Tom Vink

Paul Parren

Jan Van De Winkel

Edward Norbert Van Den Brink

David Satijn

Rik Rademaker

Pekka Kallunki

Ibrahim John Malik

Florence Sotty

Karina Fog

Louise Buur Vesterager

Liliana Christina Pereira Montezinho

Ann-Louise Bergstrôm

Janine Schuurman

Aran Frank Labrijn

Patrick Van Berkel

Willem Karel Bleeker

Joyce Meesters

Joost J Neijssen

Frank Beurskens

Bart De Goeij

Michel De Weers

Ewald T J Van Den Bremer

Rob Aalberse

Tim Walseth

Ole Baadsgaard

Rob N De Jong

Jeffrey B Stavenhagen

Maroeska Oudshoorn

Marijn Van Der Neut Kolfschote

Rene Hoet

Esther Breij

Sandra Verploegen

David P E Satijn

Vibeke Miller Breinholt

Eva Ehrnrooth

Mischa Houtkamp

Catharina Emanuele Gerarda Havenith

Marijn Van Der Neut Kolfschoten

Rene M A Hoet

Ann-Louise Bergström

Joost Melis

Hendrik Ten Napel

Ewald Van Den Bremer

Rene MA Hoet

Jan GJ Van De Winkel

Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.

Heterodimeric antibody Fc-containing proteins and methods for production thereof

The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.

Agents, uses and methods for the treatment of synucleinopathy

Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Antibodies against human CD38

The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

Bispecific antibodies and methods for production thereof

The present invention relates to novel stabilized IgG4 antibodies, to methods of producing such antibodies and to uses of such antibodies as a medicament. In a main aspect, the invention relates to a stabilized IgG4 antibody, comprising a heavy chain and a light chain, wherein said heavy chain comprises a human IgG4 constant region having a substitution of the Arg residue at position (409), the Phe residue at position (405) or the Lys residue at position (370).

Stable IgG4 antibodies

Antibodies for the treatment of synucleinopathy

Growing community of inventors

Utrecht, Netherlands

Tom Vink